Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Famciclovir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.98 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 2/20 | 0.43 |
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.40 |
| ▸ | HSP90AB1 known ✓ | P08238 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.98 |
| ▸ | HPGD | P15428 | 1/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.98 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.98 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.36 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.33 |
| ▸ | DUT | P33316 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Famciclovir SCHEMBL2949 | 0.99 | KDM4E (1.00) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| Famciclovir SCHEMBL8190642 | 0.99 | KDM4E (1.00) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| Famciclovir SCHEMBL29357294 | 0.99 | KDM4E (1.00) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| Famciclovir SCHEMBL6471652 | 0.98 | KDM4E (0.98) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| Famciclovir SCHEMBL3932051 | 0.98 | KDM4E (0.98) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| Famciclovir SCHEMBL29098544 | 0.98 | KDM4E (0.98) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| Famciclovir SCHEMBL6471750 | 0.96 | KDM4E (0.94) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| Famciclovir SCHEMBL29110632 | 0.95 | KDM4E (0.92) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| Famciclovir SCHEMBL2326990 | 0.94 | KDM4E (0.90) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| Famciclovir SCHEMBL28668832 | 0.94 | KDM4E (0.90) | KDM4EALDH1A1HPGDADRA1AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122031506-A | Chiral control | 波涛生命科学有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-115087665-A | Engineered platelets for targeted delivery of therapeutic agents | JPV01有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-114432287-A | Application of ITF2357 in preparation of medicine for preventing and treating coronavirus | 中国科学院深圳先进技术研究院 | 2022-05-06 | — | — | CN | disclosed |
| CN-114432303-A | Application of panobinostat in preparation of medicine for preventing and treating coronavirus | 中国科学院深圳先进技术研究院 | 2022-05-06 | — | — | CN | disclosed |
| CN-113813366-A | Application of romidepsin in preparation of medicine for preventing and treating novel anti-new-crown-pneumonia coronavirus | 中国科学院深圳先进技术研究院 | 2021-12-21 | — | — | CN | disclosed |
| CN-112955124-A | Oral film compositions and dosage forms having precise active dissolution profiles | 阿奎蒂夫疗法公司 | 2021-06-11 | — | — | CN | disclosed |
| CN-111467338-B | Application of pyroglutamic acid in preparation of medicine for preventing and treating novel coronavirus resistant to new coronary pneumonia | 中国科学院深圳先进技术研究院 | 2021-04-23 | — | — | CN | disclosed |
| CN-111467338-A | Application of pyroglutamic acid in preparation of medicine for preventing and treating novel coronavirus resistant to new coronary pneumonia | 中国科学院深圳先进技术研究院 | 2020-07-31 | — | — | CN | disclosed |
| CN-111420024-A | Application of bacitracin A in preparing medicine for preventing and treating coronavirus | 中国科学院深圳先进技术研究院 | 2020-07-17 | — | — | CN | disclosed |
| CN-111407754-A | Application of carglumic acid in preparing medicine for preventing and treating coronavirus | 中国科学院深圳先进技术研究院 | 2020-07-14 | — | — | CN | disclosed |
| WO-2003101476-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | NEW RIVER PHARMACEUTICALS INC. (US) | 2003-12-11 | — | — | WO | disclosed |